SkinCure Oncology
SkinCure Oncology provides a managed-services platform for Image-Guided Superficial Radiation Therapy (IG-SRT), branded as GentleCure, for non-melanoma skin cancer treatment. The company partners with 345+ dermatology practices across 48 US states, supplying equipment, staffing, and clinical protocols without upfront costs.
- Company typePrivate
- Founded2016
- HeadquartersChicago, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
SkinCure Oncology firmographics
Firmographics- Name
- SkinCure Oncology
- Legal name
- SkinCure Oncology, LLC
- Website
- https://skincureoncology.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- SkinCure Oncology provides a managed-services platform for Image-Guided Superficial Radiation Therapy (IG-SRT), branded as GentleCure, for non-melanoma skin cancer treatment. The company partners with 345+ dermatology practices across 48 US states, supplying equipment, staffing, and clinical protocols without upfront costs.
- Ownership category
- akta.pro rank
SkinCure Oncology industry classification
Industry- Product category
- Radiation Oncology Services
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mohs Surgery & Skin Cancer (Dermatologic Oncology) (HLAKACAD)
- akta.pro secondary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where SkinCure Oncology is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SkinCure Oncology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Practice Partnership Model: SkinCure Oncology partners with dermatology practices to provide IG-SRT treatment services. The company provides equipment, training, staffing (RTTs), and operational support to practices. Practices offer the GentleCure treatment to patients, with billing through insurance and Medicare. Revenue is generated through the treatment delivery ecosystem.
- Treatment Services Revenue: Revenue generated from patient treatments performed at partner dermatology practices. Treatments are covered by insurance and Medicare. The company notes reimbursement from 'all major insurance companies and Medicare.'
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance/Medicare covered treatment at partner dermatology practices |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels9 records
SkinCure Oncology product offering
Product offeringCore offering
SkinCure Oncology partners with dermatology practices across the United States to deliver Image-Guided Superficial Radiation Therapy (IG-SRT) for non-melanoma skin cancer under its GentleCure brand. The company provides a turnkey solution covering equipment procurement, regulatory compliance, room renovation, device installation, clinical training, and ongoing support including staffing with registered radiation therapists (RTTs), with no upfront costs to the practice.
Product overview
SkinCure Oncology offers a unified treatment platform centered on GentleCure, their branded Image-Guided Superficial Radiation Therapy (IG-SRT) for nonmelanoma skin cancer. The core offering combines the GentleCure treatment experience with IG-SRT technology that integrates High-Resolution Dermal Ultrasound imaging with superficial radiotherapy. The recently launched GentleBeam module adds FDA-cleared laser-induced acoustic pressure wave visualization technology to enhance precision. Together, these products enable dermatologists to deliver cancer center-level care with 99%+ cure rates, real-time tumor visualization, and adaptive dosing protocols—all within dermatology practice settings through a network of over 345 practice partners.
Differentiator
Problem solved
Functional benefit
Products and services
- GentleCure by SkinCure Oncology The branded end-to-end treatment experience for non-melanoma skin cancer that delivers cancer center-level radiotherapy in a dermatology office setting. Provided to dermatology practices as a partnership offering that includes the equipment, radiation therapist staffing, training, and ongoing clinical support; patients at partner practices receive approximately 20 sessions of 15-minute treatments with reported 99%+ cure rate and 99.8% patient satisfaction.
- Image-Guided Superficial Radiation Therapy (IG-SRT) Proprietary treatment technology combining High-Resolution Dermal Ultrasound (HRDUS) imaging with Superficial Radiation Therapy. The first and only FDA-cleared SRT technology equipped with high-frequency ultrasound imaging for non-melanoma skin cancer, enabling visualization and measurement of tumors for adaptive radiotherapy protocols.
- GentleBeam FDA-cleared imaging technology using laser-induced acoustic pressure wave technology (Photosonic) that expands image-guided visualization capabilities in dermatology practices, enabling enhanced precision during superficial radiation therapy for non-melanoma skin cancer.
Quantifiable outcome
- 99%+ cure rate for stage 0-II basal cell, squamous cell, and SCCIS carcinomas
- +5 more outcomes
Companies that use SkinCure Oncology
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles2 records
SkinCure Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
SkinCure Oncology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sensus HealthcarecoreSensus Healthcare manufactures the SRT-100 Vision device used for IG-SRT treatment. The companies resolved a prior legal dispute in May 2026 and are moving forward with shared commitment to patient care and clinical excellence. Sensus Healthcare had previously filed a lawsuit against SkinCure Oncology for breach of contract regarding unpaid equipment amounts.
Scale indicators7 records
Recent moves6 records
SkinCure Oncology competitors and assessment
Company assessmentBroad incumbents
- Accuray: Radiation therapy systems maker (CyberKnife, TomoTherapy) primarily serving hospital oncology departments. Comparable as a radiation-oncology technology incumbent, though currently focused on different clinical settings and indications.
- Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology equipment and treatment planning software. While focused on hospital-based linear accelerators rather than office-based SRT, it represents the broader incumbent ecosystem that could eventually enter office-based dermatology radiotherapy.
- Elekta: Major radiation therapy and radiosurgery equipment manufacturer serving hospitals and oncology centers. A potential horizontal competitor if it extends office-based superficial radiation offerings to dermatology.
- QualDerm Partners: PE-backed dermatology platform that serves a similar customer base and faces the same NMSC treatment economics. A potential enterprise customer for SkinCure or a competitor that develops in-house SRT capability.
- Forefront Dermatology: Large PE-backed U.S. dermatology practice network offering medical and surgical dermatology services including NMSC treatment. Potential enterprise customer or competitor in the same NMSC patient population.
- Advanced Dermatology and Cosmetic Surgery: Large multi-state dermatology practice group offering NMSC treatment including Mohs surgery. Represents both a potential large-scale channel partner and a competitor for the same patient population.
- US Dermatology Partners: One of the largest U.S. dermatology practice groups and a likely customer as well as a potential competitor that could choose to insource SRT or partner with an alternative provider. Operates in overlapping customer base (dermatology practices treating NMSC).
Emerging players
- ViewRay: Developer of MR-guided radiation therapy systems for cancer treatment. Comparable as an emerging player in image-guided radiation therapy, though operating in higher-acuity hospital settings rather than dermatology offices.
- RefleXion Medical: Emerging oncology technology company developing biology-guided radiotherapy. Represents a next-generation modality that could complement or compete with office-based superficial radiation therapy for certain skin cancer indications.
Direct peers
- Sensus Healthcare: Manufactures the SRT-100 Vision superficial radiation therapy system that SkinCure Oncology deploys and also operates its own competing SRT services business targeting dermatology practices. Sensus is simultaneously a key supplier and direct competitor in the IG-SRT market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SkinCure Oncology social profiles
Digital presenceSkinCure Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
SkinCure Oncology leadership team
Management profileNumber of profiles
Profiles7 records
SkinCure Oncology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SkinCure Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SkinCure Oncology
What does SkinCure Oncology do?
SkinCure Oncology partners with dermatology practices across the United States to deliver Image-Guided Superficial Radiation Therapy (IG-SRT) for non-melanoma skin cancer under its GentleCure brand. The company provides a turnkey solution covering equipment procurement, regulatory compliance, room renovation, device installation, clinical training, and ongoing support including staffing with registered radiation therapists (RTTs), with no upfront costs to the practice.
Is SkinCure Oncology a public or private company?
SkinCure Oncology is a private company. It is classified as private equity controlled and is currently operating.
When was SkinCure Oncology founded?
SkinCure Oncology was founded in 2016. It employs 501 to 1,000 people.
Where is SkinCure Oncology based?
SkinCure Oncology is headquartered in Chicago, United States, in the North America region.
How does SkinCure Oncology make money?
Two revenue lines are on record. Practice Partnership Model is the primary driver. The others are treatment Services Revenue.
Who are SkinCure Oncology's main competitors?
Broad incumbents on record are Accuray, Varian Medical Systems (Siemens Healthineers), Elekta, QualDerm Partners, Forefront Dermatology, Advanced Dermatology and Cosmetic Surgery and US Dermatology Partners. Emerging players are ViewRay and RefleXion Medical. Sensus Healthcare is listed as a direct peer.
Does SkinCure Oncology have an API?
No public API is recorded for SkinCure Oncology.
What industry is SkinCure Oncology in?
SkinCure Oncology's product category is Radiation Oncology Services. Its primary akta.pro industry code is HLAKACAD, Mohs Surgery & Skin Cancer (Dermatologic Oncology), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 8011.